By Fineline Cube CanSino Biologics (HKG: 6185) announced that it has submitted a New Drug Application (NDA) in China for its Adsorbed Acellular Diphtheria, Tetanus and Pertussis (5‑Component) Combined Vaccine for individuals aged 6 and above, referred to as Td5cp for Adolescents and Adults. The filing positions the product as the first potential adolescent and adult DTaP booster vaccine in the Chinese market.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | China NMPA |
| Submission Type | New Drug Application (NDA) |
| Product | Td5cp – Adsorbed Acellular Diphtheria, Tetanus and Pertussis (5‑Component) Combined Vaccine |
| Target Population | Individuals aged 6 and older |
| Indication | Booster vaccination against diphtheria, tetanus, and pertussis in adolescents and adults |
| Announcement Date | 17 Aug 2026 |
| Next Steps | NMPA review; potential first adolescent/adult DTaP booster approval in China |
Vaccine Profile & Positioning
- Product: Td5cp, a 5‑component acellular combined vaccine adsorbed for booster use against diphtheria, tetanus, and pertussis
- Target Population: Adolescents and adults aged 6 years and older
- Role: Booster dose to extend protection beyond childhood immunization, consistent with practice in major developed countries where such vaccines are incorporated into routine immunization schedules
- Market Gap: No adolescent and adult DTaP booster vaccine has been approved in China to date, leaving a first‑mover opportunity for Td5cp
Market Impact & Outlook
- First‑Mover Opportunity: With no approved adolescent/adult DTaP booster in China, Td5cp addresses an entirely unserved segment, creating potential to establish a new category in the domestic vaccine market.
- Alignment with Global Practice: Major developed countries already include adolescent/adult pertussis boosters in routine immunization schedules; China’s lack of an approved product represents a clear gap that public health authorities may seek to close.
- Pertussis Resurgence: Waning immunity and pertussis outbreaks in older age groups globally have reinforced the case for adolescent and adult boosting, supporting long‑term demand for the vaccine category.
- Portfolio Diversification: The NDA advances CanSino Biologics’ expansion into routine immunization and preventive care franchises with durable, recurring demand.
Forward-Looking Statements
This brief contains forward‑looking statements regarding regulatory review timelines, approval outcomes, and commercial expectations for Td5cp. Actual results may differ due to risks including NMPA review decisions, immunization policy adoption, and competitive dynamics in the vaccine market.-Fineline Info & Tech